Evidence Snapshot

RAF proto-oncogene serine/threonine-protein kinase

CHEMBL1906 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:28Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1906

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RAF proto-oncogene serine/threonine-protein kinase as ChEMBL target CHEMBL1906, mapped to UniProt P04049. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

RAF proto-oncogene serine/threonine-protein kinase

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1906

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P04049

RAF proto-oncogene serine/threonine-protein kinase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why RAF proto-oncogene serine/threonine-protein kinase matters

As of 2026-09-13

RAF proto-oncogene serine/threonine-protein kinase is reviewed as RAF proto-oncogene serine/threonine-protein kinase (UniProt P04049); RAF proto-oncogene serine/threonine-protein kinase shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 13 approved drugs, 5321 compounds, and 789 assays, with lead potency reaching pChEMBL 10.6.

Protein context

RAF proto-oncogene serine/threonine-protein kinase

RAF proto-oncogene serine/threonine-protein kinase Sequence length is 648 aa.

Review this target as RAF proto-oncogene serine/threonine-protein kinase, mapped to UniProt P04049. Sequence length is 648 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P04049 Protein

Disease context

cancer

RAF proto-oncogene serine/threonine-protein kinase shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include REGORAFENIB, SORAFENIB TOSYLATE, XL-281.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB, SORAFENIB TOSYLATE, XL-281. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 3 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 5321 compounds, and 789 assays for this target. The dominant activity type is IC50. CHEMBL3924812 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL3924812 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine

13 approved pChEMBL 10.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why RAF proto-oncogene serine/threonine-protein kinase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04049, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5321

Total Compounds

789

Total Assays

Approved Drugs

IC50: 5551.0, KI: 30.0, EC50: 24.0, KD: 509.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL3924812	10.6	IC50	—
No preferred name CHEMBL3961999	10.5	IC50	—
No preferred name CHEMBL3933272	10.4	IC50	—
No preferred name CHEMBL6023111	10.4	IC50	—
No preferred name CHEMBL3951474	10.2	IC50	—

Approved Drugs

Structure	Compound	First Approval
	TOVORAFENIB CHEMBL3348923	2024
	DABRAFENIB CHEMBL2028663	2013
	REGORAFENIB CHEMBL1946170	2012
	VEMURAFENIB CHEMBL1229517	2011
	PAZOPANIB CHEMBL477772	2009
	DASATINIB CHEMBL5416410	2006
	SORAFENIB CHEMBL1336	2005

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:28Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1906